The original trial focused on sustained remission, including clinical and biochemical remission, and endoscopic remission ...
Andy Plump, the research and development chief who overhauled Takeda's pipeline over more than a decade, will retire in June ...
Heart disease prevention targets remain unmet across Europe, with poor cholesterol and blood pressure control and low ...
Low hydroxychloroquine levels and poor adherence raises SLE atherosclerotic cardiovascular disease risk, a new study has ...
Hereditary hypotrichosis showed distinct genotype–phenotype patterns, supporting phenotype-driven candidate-gene ...
Colorectal cancer circuitry involving MYC, ETS2 and FOXP1 regulated super enhancers and highlighted LGR5 activation.
Where do you think we are still failing to translate the evidence we already have into better diabetes care, and what could ...
Unruptured brain aneurysms may affect one in 15 healthy adults, with prevalence more than doubling over the past two decades.
AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in ...
An investigational MASH drug significantly reduced liver fat after 12 weeks, with no major safety concerns in a phase 2a ...
Discover how shifting daily movement behaviors lowers cancer risk across 24 hours. Read more for clinical takeaways.
AbbVie’s atogepant has met the primary endpoint of its phase 3 trial, which tested the drug as a preventive treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results